Frankfurt am Main / Düsseldorf – A HOYNG ROKH MONEGIER litigation team led by Dr. Christine Kanz in cooperation with Bristows (lead partner: Brian Cordery) advised and represented Novo Nordisk A/S («Novo Nordisk») in successfully enforcing its patent and regulatory rights during CPHI, the leading global pharmaceutical trade fair held in Frankfurt am Main, Germany, from 28 – 30 October 2025.
Based on infringements of Novo Nordisk’s patent EP 1 863 839 B1, the 4a Civil Chamber of Düsseldorf Regional Court granted 26 ex parte preliminary injunctions against companies offering the active pharmaceutical ingredient Semaglutide and/or Semaglutide-containing pharmaceuticals at the trade fair. 25 injunctions were promptly served on the infringing exhibitors directly at the trade fair and are effective immediately.
In addition, Frankfurt Regional Court issued (6 Civil Chamber) three further ex parte preliminary injunctions against exhibitors that offered finished medicinal products containing Semaglutide without valid marketing authorization, which constitutes an infringement of unfair competition law. These injunctions were likewise enforced on-site during the event.
All defendants have the right to appeal against the injunction orders.
Raquel Frisardi, Associate General Counsel at Novo Nordisk: «These large scale enforcement actions demonstrate Novo Nordisk’s consistent commitment to protecting its groundbreaking innovations and ensuring compliance with regulatory requirements in Germany and throughout Europe.”
HOYNG ROKH MONEGIER Team: Dr. Christine Kanz (Lead, Partner), Mathis Breuer (Partner), Dr. Sandra Stolzenburg-Wiemer (Counsel), Valentin Wagner (Counsel), Dr. Claudia Hertzsch (Counsel), Max von Leitner (Senior Associate), Ling-Ling Dorsch (Senior Associate), Dr. Karsten Müller (Associate)